Biotech Values

[DewDiligence]

ENTA—It would seem to me that the value of the first gen asset (ABT-450) is largely known.

From a medical standpoint, yes, but not from a commercial standpoint. Many sell-side analysts are still predicting that ABBV/ENTA will garner 15% or less of the GT1 market in the US and EU (compared to my forecast of 38% volume share).

As more analysts raise their market-share forecasts for the 3-DAA regimen, ENTA’s share price will presumably respond accordingly.